Skip to main content
Top
Published in: International Journal of Hematology 4/2002

01-05-2002 | Review Article

Leukemogenic Risk of Hydroxyurea Therapy as a Single Agent in Polycythemia Vera and Essential Thrombocythemia: N-and K-ras Mutations and Microsatellite Instability in Chromosomes 5 and 7 in 69 Patients

Authors: Despina Mavrogianni, Nora Viniou, Evi Michali, Evangelos Terpos, John Meletis, George Vaiopoulos, Marina Madzourani, Gerasimos Pangalis, Xenophon Yataganas, Dimitris Loukopoulos

Published in: International Journal of Hematology | Issue 4/2002

Login to get access
Metadata
Title
Leukemogenic Risk of Hydroxyurea Therapy as a Single Agent in Polycythemia Vera and Essential Thrombocythemia: N-and K-ras Mutations and Microsatellite Instability in Chromosomes 5 and 7 in 69 Patients
Authors
Despina Mavrogianni
Nora Viniou
Evi Michali
Evangelos Terpos
John Meletis
George Vaiopoulos
Marina Madzourani
Gerasimos Pangalis
Xenophon Yataganas
Dimitris Loukopoulos
Publication date
01-05-2002
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2002
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02982131

Other articles of this Issue 4/2002

International Journal of Hematology 4/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine